Checkout View Cart Items

Program Highlight

The 1st Annual Cell Therapy Industry Summit will provide an excellent opportunity for thought leaders to celebrate cell therapy industry achievements and disseminate best practices. The meeting is designed specifically to serve the networking and informational needs of cell therapy industry leaders and limited in attendance to ensure participants are able to engage in meaningful discussions about mutually beneficial industry trends, dynamics and opportunities.

Photos From The Summit

 
 
 

  • Greg Lucier, Chairman and CEO , Life Technologies Corporation
  • Tom Okarma, President and CEO, Geron Corporation
  • Geoff MacKay, President and CEO, Organogenesis Inc.
  • Edward Lanphier, President and CEO, Sangamo BioSciences, Inc.
  • Neil K. Warma, President & CEO, Opexa Therapeutics, Inc.
  • James Noble, CEO, Adaptimmune Ltd.
  • Deborah Eppstein, President, CEO, and Director, Q Therapeutics, Inc
  • Robert J. Harman, Founder and CEO, Vet-Stem
  • Duane J. Roth, CEO and member of the Board of CONNECT
  • Eduardo Bravo, CEO, Cellerix
  • Alan Trounson, President, California Institute for Regenerative Medicine
  • Edward L. Field, President and COO, Aldagen
  • Robert A. Preti, President and CSO, Progenitor Cell Therapy LLC
  • Allan Robins, Vice President and CTO, Novocell, Inc.
  • Weng Tao, Vice President, Research & Development and CSO, Neurotech
  • Michael Schuster, Vice President of Operation, Angioblast Systems, Inc.
  • Vern L. Liebmann, Vice President, Operations, Aderans Research
 
  • Dushyant Pathak, Vice President of Business Development, iPierian, Inc.
  • Tom Novak, Head of Discovery Technologies, Roche Palo Alto
  • Kenneth K. Kleinhenz, Vice President of Regulatory Affairs, Cytori Therapeutics Inc.
  • Nicole Provost, Vice President of Product Development, Dendreon Corporation
  • Rajesh Chopra, Vice President of Translational Research, Celgene Corporation
  • Jason Krentz, Executive Director, Technical Operations, Tengion, Inc.
  • Katie Faria, Director of Process Development, Organogenesis Inc.
  • David DiGiusto, Director of Cellular Process Development and Manufacturing, City of Hope National Medical Center
  • Ron Jankowski, Director of Research and Product Development, Cook MyoSite
  • Wouter Van’t Hof, Director of Regenerative Medicine, Athersys, Inc.
  • Juliana Blum, Director of Business Operations and Co-founder, Humacyte, Inc.
  • Ralph Brandenberger, Director Process Sciences, Geron Corporation
  • Doris Taylor, Director of the Center for Cardiovascular Repair, University of Minnesota
  • Joyce L. Frey-Vasconcells, Executive Director, Pharmanet Consulting               



   
 
 
WEDNESDAY, NOVEMBER 11
6:00pm - 9:00pm Pre-conference networking event & cocktail reception
 
THURSDAY, NOVEMBER 12
7:00am - 8:00am Breakfast
8:00am - 10:00am Session 1: Leading in regenerative medicine.
 

• Shaping the regulatory environment through scientific excellence
• Personalized medicine in action
• Driving shareholder value through cell therapy


Moderator:
Greg Lucier, Life Technologies Corporation
Speakers:
Tom Okarma, Geron Corporation
Geoff MacKay, Organogenesis, Inc
Eduardo Bravo, Cellerix
Alan Trounson, California Institute for Regenerative Medicine

10:00am - 10:30am Morning Coffee
10:30am - 12:00pm Session 2: Stepping into regenerative medicine.
 

• Growth opportunities in cell therapy
• Barriers investment in cell therapy
• Partnership models for success


Moderator:
Paul Pickering, Life Technologies Corporation
Speakers:
Tom Novak, Roche Palo Alto
Rajesh  Chopra, Celgene Corporation
Neil K. Warma, Opexa Therapeutics, Inc

12:00pm - 1:00pm Lunch
1:00pm - 2:30pm Breakout Sessions
 

Session 1:
Gene modification

Gene modification systems and processes, vector design and production issues, safety and regulatory concerns, and the future of cell-based gene therapy


Moderator:
Mark Bonyhadi, Life Technologies Corporation
Speakers:
Dave DiGuisto, City of Hope
Weng Tao, Neurotech
Edward Lanphier, Sangamo BioSciences, Inc
James Noble, Adaptimmune Ltd.      


Session 2:
Stem cell scale up

Scale up considerations and technologies critical for providing stem cells at phase appropriate levels to support development from pre-clinical evaluations through commercialization


Moderator:
Eric Roos, Life Technologies Corporation
Speakers:
Ralph Brandenberger, Geron Corporation
Wouter Vant Hof, Athersys, Inc
Allan Robins, Novocell, Inc


Session 3:
More with less

Efforts to economize cell therapy manufacturing through items such as raw material sourcing, process efficiencies and automation.


Moderator:
Brian Newsom, Life Technologies Corporation
Speakers:
Katie Faria, Organogenesis
Ron Jankowski, Cook MyoSite
Juliana Blum, Humancyte
Jason Krentz, Tengion, Inc.

2:30pm - 3:00pm Afternoon Break
3:00pm - 5:00pm Session 4: Models for expedited commercialization.
 

• Opportunities for expedited regulatory clearance
• Novel go-to-market strategies
• Cash flow positive business models which build to therapeutic outcomes


Moderator:
Joydeep Goswami, Life Technologies Corporation
Speakers:
Dushyant Pathak, iPierian, Inc.
Kenneth K. Kleinhenz, Cytori Therapeutics
Duane J. Roth, CONNECT
Joyce L. Frey-Vasconcells, Pharmanet Consulting

5:30pm - 8:00pm Networking reception and Dinner
 
FRIDAY, NOVEMBER 13
7:00am - 8:00am Breakfast
8:00am - 10:00am Session 1: Expanding your business with novel cell therapy platforms.
 

• Point of care for autologous therapy
• Novel differentiated cell populations
• Mobilization of endogenous progenitor


Moderator:
Mahendra Rao, Life Technologies Corporation
Speakers:
Deborah Eppstein, Q Therapeutics
Doris Taylor, University of Minnesota
Nicole Provost, Dendreon
Robert J. Harman, Vet-Stem

10:00am - 10:30am Morning Coffee
10:30am - 12:00pm Session 2: Building a sustainable cell therapy business: The make vs. buy decision.
 

• Key parameters to consider in making your decision
• The influence of clinical development stage
• How to smooth the transition between manufacturing models


Moderator:
Nicolas Barthelemy, Life Technologies Corporation
Speakers:
Vern L. Liebmann, Aderans Research
Edward L. Field, Aldagen
Robert A. Preti, Progenitor Cell Therapy LLC
Michael Schuster, Angioblast Systems, Inc.